TROPION-Lung01 Study Design and Baseline demographics
Background
Standard-of-care, second-line chemotherapy for metastatic NSCLC
is associated with a modest benefit and substantial toxicity
• Dato-DXd is a TROP2-directed ADC that selectively delivers a
potent topoisomerase I inhibitor payload directly into tumor cells¹
Promising antitumor activity was seen with Dato-DXd in patients
with adv/met NSCLC in the phase 1 TROPION-PanTumor01 trial
(26% ORR)1
Dato-DXd: Humanized anti-TROP2
IgG1 mAb²-5
Deruxtecan
H
H.C-
Daiichi-Sankyo
HO
-CH₂
Cleavable
tetrapeptide-based linker
Topo-l inhibitor payload
(DXd)
Image is for illustrative purposes only; actual drug positions may vary.
ADC, antibody-drug conjugate; adv/met, advanced/metastatic; Dato-DXd, datopotamab deruxtecan; IgG1, immunoglobulin G1; mAb, monoclonal antibody; NSCLC, non-small cell lung cancer; ORR, objective response rate;
TROP2, trophoblast cell-surface antigen 2.
1. Shimizu T, et al. J Clin Oncol. 2023;41:4678-4687. 2. Okajima D, et al. Mol Cancer Ther. 2021;20:2329-2340. 3. Nakada T, et al. Chem Pharm Bull (Tokyo). 2019;67:173-185. 4. Ogitani Y, et al. Clin Cancer Res.
2016;22:5097-5108. 5. Ogitani Y, et al. Cancer Sci. 2016;107:1039-1046.
5View entire presentation